MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.14
+1.34
+2.93%
After Hours: 47.14 0 0.00% 16:19 09/17 EDT
OPEN
45.85
PREV CLOSE
45.80
HIGH
47.22
LOW
45.11
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
62.16
52 WEEK LOW
32.47
MARKET CAP
2.78B
P/E (TTM)
-8.5651
1D
5D
1M
3M
1Y
5Y
Agios Pharmaceuticals Sponsored Study Titled 'A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease' Posted To ClinicalTrials.gov, Shows Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05031780
Benzinga · 09/02 14:14
Agios To Present at September Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company ...
GlobeNewswire · 08/30 11:00
Thermo Fisher wins FDA nod for companion diagnostic targeting specific bile-duct cancer
The FDA has granted the pre-market approval for the Oncomine Dx Target Test developed by Thermo Fisher Scientific (NYSE:TMO) for use in the identification of patients with a specific genetic
Seekingalpha · 08/26 12:33
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
Investor Place · 08/25 16:08
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
Zacks.com · 08/18 14:05
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
Agios' Rare Anemia Drug Application Under FDA Priority Review
The 
Benzinga · 08/18 11:03
BRIEF-Agios Announces FDA Acceptance And Priority Review Of New Drug Application For Mitapivat For Treatment Of Adults With Pyruvate Kinase Deficiency
reuters.com · 08/17 20:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGIO. Analyze the recent business situations of Agios through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGIO stock price target is 62.43 with a high estimate of 93.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 276
Institutional Holdings: 71.32M
% Owned: 120.99%
Shares Outstanding: 58.95M
TypeInstitutionsShares
Increased
49
5.73M
New
38
628.72K
Decreased
61
2.57M
Sold Out
27
3.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Chief Accounting Officer
T. J. Washburn
Chief Scientific Officer
Bruce Car
Other
Sarah Gheuens
Other
Darrin Miles
Lead Director/Independent Director
John Maraganore
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
David Scadden
No Data
  • All
  • Financials
  • Insiders
More
About AGIO
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.